Compare Dollar Tree, Inc. (DLTR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Moderna, Inc. — how do they compare? Dollar Tree, Inc. trades at $128.1 (market cap $24.61B), while Moderna, Inc. trades at $60.45 (market cap $24.18B). The key difference: Dollar Tree, Inc. and Moderna, Inc. are close in size by market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| DLTR | MRNA | |
|---|---|---|
Market Cap | $24.61B | $24.18B |
Sector | Health | Health |
52-Week High | $141.21 | $81.80 |
52-Week Low | $85.04 | $22.36 |
Enterprise Value | $31.20B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $129.37, down 1.17% today but remains in a bullish technical trend with strong support near $128. The company reported a net loss of $3.03B for 2025 due to a significant tax charge, though operating cash flow improved to $2.86B. Recent earnings have consistently beaten estimates, and a new $2.5B share repurchase program signals management confidence.
The outlook is mixed: robust cash generation and positive earnings surprises support upside, but margin pressures from tariffs and intense discount retail competition pose risks. Analyst consensus is a Buy with a $126.69 price target, slightly below current levels, indicating cautious optimism amid operational challenges.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
